Safety, Pharmacokinetics, and Pharmacodynamics of Oral Venglustat in Patients with Parkinson’s Disease and a Mutation: Results from Part 1 of the Randomized, Double-Blinded, Placebo-Controlled MOVES-PD Trial

Background: Glucocerebrosidase gene ( GBA ) mutations influence risk and prognosis of Parkinson’s disease (PD), possibly through accumulation of glycosphingolipids, including glucosylceramide (GL-1). Venglustat is a novel, brain penetrant glucosylceramide synthase inhibitor. Objective: Evaluate veng...

詳細記述

書誌詳細

主要な著者:	M. Judith Peterschmitt, Hidemoto Saiki, Taku Hatano, Thomas Gasser, Stuart H. Isaacson, Sebastiaan J.M. Gaemers, Pascal Minini, Stéphane Saubadu, Jyoti Sharma, Samantha Walbillic, Roy N. Alcalay, Gary Cutter, Nobutaka Hattori, Günter U. Höglinger, Kenneth Marek, Anthony H.V. Schapira, Clemens R. Scherzer, Tanya Simuni, Nir Giladi, Sergio Pablo Sardi, Tanya Z. Fischer
フォーマット:	Artigo
言語:	Inglês
出版事項:	SAGE Publishing 2022-02-01
シリーズ:	Journal of Parkinson’s Disease
オンライン･アクセス:	https://doi.org/10.3233/JPD-212714
タグ:	タグ追加 タグなし, このレコードへの初めてのタグを付けませんか!